Current Report Filing (8-k)
September 23 2022 - 5:08PM
Edgar (US Regulatory)
0000887247
false
0000887247
2022-09-23
2022-09-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September
23,
2022
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
0-26372 |
|
82-0429727 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.)
|
11682 El Camino Real, Suite 300
San Diego, CA |
|
92130 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 997-2400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock |
|
ADMP |
|
NASDAQ Capital Market |
On September 23, 2022, Adamis Pharmaceuticals Corporation (the “Company”)
filed with the Securities and Exchange Commission (the “Commission”) a prospectus supplement dated September 23, 2022 (the
“Prospectus Supplement”), pursuant to Rule 424(b) under the Securities Act of 1933, as amended. The Prospectus Supplement
was filed pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-267365), filed with
the Commission on September 9, 2022. The Prospectus Supplement was filed to register the issuance and sale by the Company from time to
time of up to 13,794,000 shares of the Company’s common stock issuable upon the exercise of certain outstanding warrants.
Item 9.01 |
Financial Statement and Exhibits. |
(d) Exhibits.
Exhibit
No. |
|
Description |
|
|
5.1 |
|
Opinion of Latham & Watkins, LLP |
23.1 |
|
Consent of Latham & Watkins, LLP (included in Exhibit 5.1) |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION |
|
|
|
|
|
|
Dated: September 23, 2022 |
By: |
/s/ David C. Benedicto |
|
Name: |
David C. Benedicto |
|
Title: |
Chief Financial Officer |
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024